Intelligence / Semaglutide

Semaglutide

Prescription Only
GLP-1 Agonist
Schedule
S4
Prescription Only
Enforcement
Tightening
Low Risk
Providers
12
Access: Clear
Key Facts
Schedule 4 - Prescription Only
GLP-1 receptor agonist
TGA-approved branded products available
Compounded versions under increased scrutiny
Import restrictions tightened February 2026

Overview

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management. It is available in Australia as branded products (Ozempic, Wegovy) and through compounding pharmacies. The TGA has increased regulatory scrutiny on compounded versions following supply shortages.

Australian Scheduling

Schedule 4 (Prescription Only). TGA-approved branded products are listed on the ARTG. Compounded semaglutide is available under pharmacy compounding exemptions. Import restrictions were tightened in February 2026.

Access Pathway

Available through telehealth clinics and compounding pharmacies. Branded versions (Ozempic, Wegovy) can be prescribed by any GP. Compounded versions are available through specialised providers but face increasing regulatory scrutiny.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.
Behavioural pharmacology2 June 2026
15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.
Proceedings of the National Academy of Sciences of the United States of America2 June 2026
Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
PharmacoEconomics2 June 2026
Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use.
Eur J Gastroenterol Hepatol1 June 2026
[Advances in Anti-Dementia Therapies in Older Adults].
Dtsch Med Wochenschr1 June 2026
GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
Dermatol Surg1 June 2026
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
Clinical pharmacokinetics1 June 2026
After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care
J Med Internet Res28 May 2026
Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer
Pharmacol Rep28 May 2026
Differential Biliary Adverse Event Signals Among GLP-1 Receptor Agonists: A FAERS Disproportionality Analysis
Dig Dis Sci28 May 2026
Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018-2024)
Lancet Reg Health Eur27 May 2026
Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes
Graefes Arch Clin Exp Ophthalmol27 May 2026
The microdosing dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding regulation
J Am Assoc Nurse Pract26 May 2026
GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and perioperative outcomes
Surg Obes Relat Dis26 May 2026
Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight Management Program
Obes Facts25 May 2026
Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care
Am J Lifestyle Med25 May 2026
Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.
Obesity surgery23 May 2026
Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Nature medicine22 May 2026
Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.
Nature metabolism22 May 2026
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.
The lancet. Diabetes & endocrinology22 May 2026

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.